Partha Sarthy Sen
About
Partha Sarthy Sen is from 印度 马哈拉施特拉邦 孟买. Partha Sarthy works in the following industries: "制药". Partha Sarthy is currently President at First Time US Generics, located in Navi Mumbai. In Partha Sarthy's previous role as a Head Scientific Affairs Women Health Care - Senior VP at Mylan, Partha Sarthy worked in Ahmedabad Area, India until Apr 2017. Prior to joining Mylan, Partha Sarthy was a President R & D- Sidmak Laboratories (Sun Pharma Group Company) at SUN PHARMA and held the position of President R & D- Sidmak Laboratories (Sun Pharma Group Company) at Valsad. Prior to that, Partha Sarthy was a AGM at Cadila Pharmaceuticals Limited, based in Ahmedabad Area, India from Apr 2001 to Nov 2002. Partha Sarthy started working as Senior Manager at Ajanta Pharma Ltd in Mumbai Area, India in May 1999. From Apr 1995 to Apr 1999, Partha Sarthy was Deputy Manager at AstraZeneca, based in Karnataka, India. Prior to that, Partha Sarthy was a Executive at Lupin, based in Aurangabad Area, India from Jul 1991 to Mar 1995.
If you’re looking for Partha Sarthy Sen's email address, you can find it on finalscout.com. Finalscout is a professional database with more than 500 million business professionals and 200 million company profiles.
Partha Sarthy Sen's current jobs
President-. Responsible for Complete Indian Operation that includes compliance, business development, Product development ,Patent, Technology transfer and regulatory requirements Instrumental in facility upgradation, NABL approval, USFDA approval, several ANDAs,ANADA's, OTC products , device Class 1 development and launch.
Partha Sarthy Sen's past jobs
Helped in Due diligence during take over of famycare Approved ANDA includes generic equivalent to Depo- Provera (DMPA) and several oral contraceptives, that makes multi billion dollar products for Mylan. Commercialized 36 approved products and had atleast 6 Pivotal BE passed during the period of stay. Atleast 150 products were registered in regulated and semiregulated countries of already developed products.
Has developed several Controlled and Sustained release bioequivalent products using inhouse platform technologies. The technologies provided Zero order release similar to OROS technology but is patent non infringing. There are first to file approved products. A bioequivalent and clinically approved transdermal product is ready but not submitted yet. Many BCS Class IV and difficult to achieve bioequivalence products successfully developed. Several liquid products developed for customers Many difficult to stabilize and combination products successfully marketed. More than 50 products for USA developed and several approved US ANDA The company turn over increased several folds due to introduction of new products for domestic and USA. As R & D revenues, the company earned about Rs 200 cr in 6 years as part of development charges and royalties. 4 promotions in 7 years to become President from GM
Launched more than 100 products including certain patented products and first to file products for Indian and ROW market. The turn over of company doubled with the introduction of products.
Launched around 50 domestic products and some innovative patented products as part of All India 600 project that made Ajanta Pharma a successful company over the years .
Had launched products like aerosols, vaginal delivery devices, injections, Durules (Zero order release products) , soft gelatin capsule , etc., in both domestic and ROW market that saw several fold sales increase of Indian operation.
Launched several new products that became multi billion products by sales that included Cephalosporin range, Anti TB range and several brands in domestic that became blockbuster products over the years. Some of the products were exported to China and other countries.